Pharmaceuticals, Biotechnology and Life Sciences
New research published in the European Journal of Nutrition found that daily consumption of the equivalent of one cup of fresh blueberries, given as 24 g of freeze-dried powder, showed …
Arix Bioscience and Takeda will work together to combine complementary skills and experience across important therapeutic areas in a strategic deal.
Conceiving and bearing a child is a blessing in a couple’s life. While they are lost in rejoicing the good news, they often ignore the fact that they can be passing some serious genetic disorders to their child. Along with the features and traits, a child also inherits genetic disorders which their parents are the carrier.
Novo Nordisk has submitted a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for semaglutide, a new glucagon-like peptide-1 (GLP-1) analogue administrated once-weekly, for the treatment of adults with type 2 diabetes.
Premaitha Health, an international molecular diagnostics group focused on prenatal testing, has acquired Taiwanese Yourgene Bioscience.
Growing prevalence of chronic diseases, surge in clinical trials outsourcing, rising R&D cost and favorable government initiatives will drive global clinical trial management system market size, according to a report by Global Market Insights.
For mountain climbers and hikers, injuries often include broken bones, sprains and skin wounds, but many don’t carry the right supplies for the injuries and illnesses they are most likely to face, a recent study found.
Oncology drug research and development company Xynomic Pharmaceuticals has acquired exclusive worldwide rights to develop a novel HDAC inhibitor targeting hematological and solid tumors, Abexinostat.
China has updated list of medicines covered by basic medical insurance schemes, a long-awaited fillip for drugmakers in the world’s second-largest drug market where many new drugs have been kept out of patients’ reach because of high costs.
Neovacs has signed with BioSense Global a commercial license option agreement for its IFNalpha Kinoid vaccine to treat lupus and dermatomyositis in China, worth up to €65 million in upfront and milestone payments, not including double-digit sales royalties.